share_log

Zhe Jiang Dayang Biotech Group's (SZSE:003017) Soft Earnings Are Actually Better Than They Appear

Zhe Jiang Dayang Biotech Group's (SZSE:003017) Soft Earnings Are Actually Better Than They Appear

浙江大洋生物科技集团(SZSE:003017)的净利润表现实际上比表面看起来要好
Simply Wall St ·  10/25 18:32

Soft earnings didn't appear to concern Zhe Jiang Dayang Biotech Group Co., Ltd.'s (SZSE:003017) shareholders over the last week. We think that the softer headline numbers might be getting counterbalanced by some positive underlying factors.

在过去的一周里,浙江大洋生物集团股份有限公司(SZSE:003017)的股东似乎并不担心盈利软化。我们认为,更软的业绩数据可能会被一些积极的基本因素所抵消。

big
SZSE:003017 Earnings and Revenue History October 25th 2024
深圳证券交易所:003017 营收和盈利历史数据 2024年10月25日

How Do Unusual Items Influence Profit?

非常规项目如何影响利润?

Importantly, our data indicates that Zhe Jiang Dayang Biotech Group's profit was reduced by CN¥13m, due to unusual items, over the last year. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And, after all, that's exactly what the accounting terminology implies. Assuming those unusual expenses don't come up again, we'd therefore expect Zhe Jiang Dayang Biotech Group to produce a higher profit next year, all else being equal.

重要的是,我们的数据显示,浙江大洋生物集团去年因飞凡项目减少了1300万人民币的利润。看到飞凡项目影响公司利润并不是好事,但好消息是,情况可能比预期好得多。我们研究了成千上万家上市公司,发现飞凡项目往往是一次性的。而且,这正是会计术语所暗示的。假设这些飞凡费用不会再次出现,我们预计浙江大洋生物集团明年的利润将更高,其他条件保持不变。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Zhe Jiang Dayang Biotech Group.

注:我们始终建议投资者检查资产负债表的实力。点击这里查看我们对浙江大洋生物集团资产负债表的分析。

Our Take On Zhe Jiang Dayang Biotech Group's Profit Performance

我们对浙江大洋生物集团的盈利表现看法

Because unusual items detracted from Zhe Jiang Dayang Biotech Group's earnings over the last year, you could argue that we can expect an improved result in the current quarter. Because of this, we think Zhe Jiang Dayang Biotech Group's earnings potential is at least as good as it seems, and maybe even better! On the other hand, its EPS actually shrunk in the last twelve months. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. If you want to do dive deeper into Zhe Jiang Dayang Biotech Group, you'd also look into what risks it is currently facing. While conducting our analysis, we found that Zhe Jiang Dayang Biotech Group has 1 warning sign and it would be unwise to ignore this.

由于飞凡项目在过去一年中损害了浙江大洋生物科技集团的收入,因此可以说我们可以期待当季的表现会有所改善。因此,我们认为浙江大洋生物科技集团的收益潜力至少和表面看起来一样好,甚至可能更好!另一方面,其每股收益在过去十二个月实际上有所下降。本文的目标一直是评估我们能否依赖法定收入来反映公司的潜力有多好,但还有很多其他因素需要考虑。如果您想更深入地研究浙江大洋生物科技集团,您还应该考虑它目前面临的风险。在进行分析时,我们发现浙江大洋生物科技集团有一个警告信号,忽视这一点是不明智的。

This note has only looked at a single factor that sheds light on the nature of Zhe Jiang Dayang Biotech Group's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

这份注意事项只关注了一个能揭示浙江大洋生物科技集团利润性质的因素。但如果你有能力专注于细枝末节,总会有更多发现。例如,很多人认为高股本回报率是有利的商业经济的指标,而另一些人则喜欢“追踪资金”并寻找内部人员正在买入的股票。虽然这可能需要您做一些研究,但您可能会发现这份自由收集的公司中股本回报率高,或者拥有重要内部持股的股票清单会很有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发